coffeesheaded by Eduardo Pastor, Continuing to lead the pharmaceutical distribution industry in SpainAs can be seen from the 2022 figures, an increase of 7%-8% and turnover of around 4,000 million eurosall-time high.
Thus, the group’s market share reached 30%. The increase in billing is notable, as Cofares billed around 3,600 million euros in 2021 with a share of just over 29%.
Born in 1944, the group lives and works in the town of Alcobendas, Madrid. 100% of its capital is in the hands of pharmaceutical partners, legally protected. It also integrates brands such as Farmavenix or Profarco, which group all Cofares stores.
It is remotely followed by Andalusia Bidafarma.Led by Granada-based Antonio Mingorance with a 21.74% market share. The company was established in 2016, has 100% pharmaceutical capital without legal protection and was formed as a result of the merger of 12 cooperatives.
Bidafarma has invoiced close to 2,600 million Euros, compared to 2,536 million Euros reached in 2020. The company has not yet registered the relevant accounts for 2021 in the trade registry, but it transmits these figures on its website.
on his behalf hephameEnrique Ayuso, group based in Murcia, It is the third company by market share., 11.05% in 2021. In the same year, the firm invoiced a turnover of 1,455 million euros, compared to 1,411 million euros in 2020. In fourth place, Alliance Healthcare, a group owned by American AmerisourceBergen, reached a quota of 10.37%. . The company is headquartered in Zaragoza and delivered revenues of € 1,275 million in 2021 compared to € 1,201 million in 2020.
These four companies represent more than 70% of the total market. The turnover of all exceeds 12,000 million euros in 2021 for a total of more than 22,000 pharmacies; according to information made public by the distributors themselves and the Trade Registry.
This week, the industry meets exactly the expected 30,000 professionals in the INFARMA hall of Fira de Barcelona, and experts think the distribution is already perfectly normal after years of the pandemic; and with a corresponding growth prospect.
This sector is undoubtedly strategic for Spanish society, and this is acknowledgment from Brussels, where the European Parliament’s Committee on Civil Liberties, Justice and Home Affairs confirmed in its report that pharmaceutical distributors constitute “vital services for the population”. The Spanish drug model is considered one of the best in the world. One of the most productive and with a strong social commitment.